PolyNovo (ASX:PNV): Revenue Growth and NovoSorb Commercial Expansion

Aditi Sarkar

14 August 2026 12:30 PM AEST

PolyNovo (ASX:PNV): Revenue Growth and NovoSorb Commercial Expansion

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

PolyNovo (ASX:PNV) reported FY26 Revenue of A$150 million, up 16.1% on a reported basis.
The company generated positive free Cash Flow of A$10.4 million for the first time.
US commercial sales reached A$102.1 million and remained the largest contributor to revenue.
NovoSorb BTM and MTX continued driving growth across wound-care applications.

PolyNovo (ASX:PNV) has reached a key financial milestone after reporting record FY26 revenue and positive free cash flow, supported by continued growth in its NovoSorb wound-care platform.

The company’s latest update highlights increasing commercial scale, particularly in the United States, while investors continue monitoring profitability, geographic concentration and future expansion.

What Happened?

On 23 July 2026, PolyNovo released preliminary unaudited FY26 results for the year ended 30 June 2026.

The company reported group revenue of A$150 million, representing growth of 16.1% on a reported basis and 20.3% on a constant-currency basis compared with A$129.2 million in FY25.

Free cash flow turned positive at A$10.4 million, compared with a negative A$10.1 million in FY25.

The United States remained the company’s largest market, with commercial sales of A$102.1 million, representing approximately 74% of commercial revenue.

Full audited financial results, including final profit measures, were scheduled for release later in August 2026.

Why It Matters

The move into positive free cash flow represents a change in PolyNovo’s financial profile.

Medical technology companies often require ongoing Investment in sales infrastructure, Manufacturing capacity and regulatory activities before reaching self-funded operations.

Generating cash from operations reduces reliance on external funding to support expansion.

The revenue milestone also demonstrates increasing adoption of NovoSorb products, particularly within the US healthcare market.

However, the company’s financial performance still requires confirmation through audited Earnings results, including profitability measures.

The Numbers

PolyNovo reported total group commercial sales of A$138.4 million, up 16.7%.

NovoSorb BTM (Biodegradable Temporising Matrix), the company’s primary product used in burns and complex trauma reconstruction, generated commercial sales of A$125.8 million, representing growth of 12.3%.

NovoSorb MTX, a dermal matrix product, recorded commercial sales of A$12.6 million, increasing 89.6% from the prior year.

Operating cash flow was approximately A$24 million, including around A$3.5 million of insurance receipts.

The company ended FY26 with A$35.4 million in cash, compared with A$33.5 million previously.

All reported financial figures are in Australian dollars.

The Bigger Picture

PolyNovo’s commercial strategy is built around NovoSorb, a synthetic biodegradable polymer platform designed to support tissue regeneration.

NovoSorb BTM is focused on burns and complex wounds, while NovoSorb MTX expands the platform into broader dermal wound applications.

The growth of MTX from a smaller base indicates the company is broadening its product portfolio beyond its original BTM market.

The United States remains the core commercial opportunity, with advanced wound-care markets providing significant Demand potential.

The company is also progressing manufacturing expansion to support future production requirements.

The Bull Case

The positive case for PolyNovo (ASX:PNV) is based on continued adoption of NovoSorb products and improving financial self-sufficiency.

The company has demonstrated revenue growth while expanding its presence across US hospitals.

Growth in MTX provides an additional product opportunity alongside the established BTM franchise.

Positive free cash flow may provide greater flexibility to fund commercial expansion, manufacturing investment and product development activities.

Further international expansion and regulatory approvals could increase future market access.

Risks Investors Should Understand

PolyNovo (ASX:PNV)’s Business faces risks including US market concentration, competition, manufacturing execution and uncertainty around final profitability.

Approximately 74% of commercial sales are generated from the United States, increasing exposure to reimbursement conditions, competitive dynamics and currency movements.

The wound-care market includes established global competitors, requiring continued surgeon adoption and hospital acceptance.

Scaling manufacturing capacity and sales infrastructure also creates execution requirements.

The FY26 update did not include final EBITDA or net profit figures, meaning the Quality of Earnings requires further confirmation through audited results.

What Comes Next?

The next key milestone is the FY26 audited results expected in late August 2026.

Investors will focus on final profitability measures, FY27 outlook commentary, manufacturing expansion progress and continued growth in US sales.

Additional attention will remain on MTX adoption, international expansion and the conversion of hospital relationships into recurring product demand.

Conclusion

PolyNovo (ASX:PNV) has delivered two important milestones with A$150 million in FY26 revenue and positive free cash flow of A$10.4 million.

The company’s growth continues to be driven by NovoSorb adoption, particularly in the United States, while MTX provides an additional product growth opportunity.

However, the company remains exposed to US market concentration, competitive pressures and the need to confirm profitability through audited results.

The FY26 performance indicates commercial progress, with future outcomes dependent on sustaining revenue growth and improving operating leverage.

FAQs

Q: What products does PolyNovo develop?

A:PolyNovo develops NovoSorb regenerative wound-care products, including BTM and MTX.

Q: What revenue did PolyNovo report for FY26?

A:PolyNovo reported group revenue of A$150 million for FY26.

Q: Did PolyNovo generate positive cash flow?

A:Yes. The company reported positive free cash flow of A$10.4 million in FY26.

Q: Which market contributes most of PolyNovo’s sales?

A:The United States is the largest market, contributing approximately 74% of commercial sales.

Q: What are the key risks for PolyNovo?

A:Key risks include US market concentration, competition, manufacturing execution and profitability confirmation.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.